Abiraterone-acetate-tablets-1.jpg (Abiraterone Acetate Tablets 1)
Abirtega Tablet
Product Images NDC 82249-011
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Abirtega (NDC 82249-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Civicascript, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Abirtega-tablets-250mg-120s-2laabi250tca-e-10-2024.jpg (Abirtega Tablets 250mg 120s 2laabi250tca E 10 2024)
This is a description for the prescription drug Abirtega (abiraterone acetate tablets, USP) 250 mg, with a warning for pregnant women to not handle the tablets without gloves. The tablets should be swallowed whole and not crushed or chewed. Each tablet contains 250 mg of abiraterone acetate. The product should be stored at 20°C to 25°C and dispensed in a child-resistant closure container. It is important to keep the medication out of reach of children. For more information, visit civicasorpt.com/abirtega or scan the provided QR code.*
Civicascript-corporate-logo.jpg (Civicascript Corporate Logo 01)
Civicascript-corporate-logo.jpg (Civicascript Corporate Logo)
Figure-1 (Image 01)
The text provides survival data over time for patients taking Abiraterone Acetate compared to the placebo. The numbers represent the number of patients alive at different time intervals, with the given time to death in months. This data can be used to evaluate the effectiveness of Abiraterone Acetate in prolonging survival compared to the placebo.*
Figure-2 (Image 02)
This description shows the comparison between Abiraterone Acetate and placebo in terms of the percentage of subjects without death over a period of 60 months from randomization. The table includes data for both groups at different time points, with the number of subjects indicated for each group. This information could be useful for evaluating the impact of Abiraterone Acetate on mortality outcomes relative to placebo.*
Figure-3 (Image 03)
This is a chart showing the number of patients receiving Abiraterone Acetate or Placebo over a period of 15 months. The data suggests a significant difference in the number of patients between the two groups at various time points. Abiraterone Acetate had higher numbers initially which declined over time, while Placebo had lower numbers that also decreased over the 15 months.*
Figure-4 (Image 04)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
